Noticias y vídeos - KIADIS

Amsterdam, The Netherlands, 13 May 202 1 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS) , a clinical-stage biopharmaceutical company, today announces that its Annual General Meeting of shareholders (" AGM ”) will be held at 15:00 CEST on 28 June 2021. Pursuant to temporary emergency legislation regarding COVID-19 in The Netherlands, the AGM can only be accessed electronically. This means that it will not be possible to attend the AGM in...

This is a joint press release by Sanofi Foreign Participations B.V. (the “ Offeror ”), Sanofi (“ Sanofi ” ) and Kiadis Pharma N.V. ( “ Kiadis ” ), pursuant to the provisions of Article 17 paragraph 4 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft , the “ Decree ” ) in connection with the recommended public offer by the Offeror for all the issued and outstanding ordinary s hares in the capital of Kiadis (the “ Offer ” ) . This announcement...

This is a joint press release by Sanofi Foreign Participations B.V. (the “ Offeror ”), Sanofi (“ Sanofi ” ) and Kiadis Pharma N.V. ( “ Kiadis ” ) in connection with the recommended public offer by the Offeror for all the issued and outstanding ordinary s hares in the capital of Kiadis (the “ Offer ” ) . This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of the offer...

This is a joint press release by Sanofi Foreign Participations B.V. (the “ Offeror ”), Sanofi (“ Sanofi ”) and Kiadis Pharma N.V. (“ Kiadis ”) in connection with the public offer by the Offeror for all the issued and outstanding ordinary shares in the capital of Kiadis (the “ Offer ”). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of the offer memorandum dated 10...

This is a joint press release by Sanofi Foreign Participations B.V. (the “ Offeror ”), Sanofi (“ Sanofi ”) and Kiadis Pharma N.V. (“ Kiadis ”), pursuant to the provisions of Article 16, paragraph 1 and 2 and Article 17 paragraph 1 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft, the “ Decree ”) in connection with the intended public offer by the Offeror for all the issued and outstanding ordinary shares in the capital of Kiadis (the “ Offer...

This is a press release by Kiadis Pharma N.V. (“ Kiadis ”), pursuant to the provisions of Section 5 paragraphs 4 and 5 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) (the “ Decree ”) in connection with the public offer by Sanofi for all the issued and outstanding ordinary shares in the capital of Kiadis launched on February 12, 2021 (the “ Offer ”). The Offer is made only by means of the offer memorandum approved by the Dutch Authority for the Financial...

New strategic focus results in significant progress in cell based therapies Amsterdam, The Netherlands, April 7, 2021 – Kiadis Pharma N.V. (“Kiadis”, “Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS) , a clinical-stage biopharmaceutical company developing innovative NK-cell-based medicines for the treatment of life-threatening diseases, today announces its audited 2020 annual results 1 . Arthur Lahr, CEO of Kiadis, commented, “2020 can be described as a...

This is a press release by Kiadis Pharma N.V. (“ Kiadis ”) in connection with the public offer by Sanofi Foreign Participations B.V. (“the Offeror ”), a wholly owned subsidiary of Sanofi (“ Sanofi ”), for all the issued and outstanding ordinary shares in the capital of Kiadis launched on February 12, 2021 (the “ Offer ”). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means...

This is a press release by Kiadis Pharma N.V. (“ Kiadis ”), pursuant to the provisions of Section 5 paragraphs 4 and 5 and Section 6 paragraph 2 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) (the “ Decree ”) in connection with the public offer by Sanofi for all the issued and outstanding ordinary shares in the capital of Kiadis launched on 12 February 2020 (the “ Offer ”). The Offer is made only by means of the offer memorandum approved by the Dutch...

This is a joint press release by Sanofi Foreign Participations B.V. (the “ Offeror ”), Sanofi (“ Sanofi ”) and Kiadis Pharma N.V. (“ Kiadis ”), pursuant to the provisions of Article 4 paragraph 1, Article 10 paragraph 1 and 3, and Article 18 paragraph 3 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft, the “ Decree ”) in connection with the intended public offer by the Offeror for all the issued and outstanding ordinary shares in the capital of...

This is a joint press release by Sanofi (" Sanofi ") and Kiadis Pharma N.V. (" Kiadis "), pursuant to the provisions of Sections 5 paragraphs 4 and 5 and Section 6 paragraph 2 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) (the “Decree” ) in connection with the intended public offer by Sanofi for all the issued and outstanding ordinary shares in the capital of Kiadis (the “Offer” ) . This announcement does not constitute an offer, or any solicitation of any...

Amsterdam, The Netherlands, January 22, 2021 – Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS) , a clinical-stage biopharmaceutical company developing innovative NK-cell-based medicines for the treatment of life-threatening diseases, today announces that four abstracts related to its K-NK-cell therapy platform were accepted for presentation at the TCT Meetings, the Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and...

This is a press release by Kiadis Pharma N.V. pursuant to Section 17 paragraph 1 of the European Market Abuse Regulation (596/2014) and in connection with the intended public offer by Sanofi for all the issued and outstanding ordinary shares in the capital of Kiadis Pharma N.V. (the "Offer"). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of an offer memorandum approved by the Dutch...

This is a joint press release by Sanofi (" Sanofi ") and Kiadis Pharma N.V. (" Kiadis "), pursuant to the provisions of Section 4, paragraph 3 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft) and Section 17 paragraph 1 of the European Market Abuse Regulation (596/2014), in connection with the intended public offer by Sanofi for all the issued and outstanding ordinary shares in the capital of Kiadis (the " Offer "). This announcement does not constitute an offer,...

This is a press release by Kiadis Pharma N.V. ( Kiadis ), pursuant to the provisions of Sections 5 paragraphs 4 and 5 and 6 paragraph 2 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) in connection with the intended public offer by Sanofi for all the issued and outstanding ordinary shares in the capital of Kiadis (the Offer ). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be...

~Five presentations related to Kiadis’ K-NK cell therapy platform will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition~ An oral presentation (abstract #68) presents data that show multiple infusions of FC21-NK cells in patients with relapsed and refractory acute myeloid leukemia (R/R AML) yielded impressive outcomes with no infusion reactions or toxicities A poster presentation (abstract #825) describes data demonstrating NKTR-255 significantly...

This is a joint press release by Sanofi (" Sanofi ") and Kiadis Pharma N.V. (" Kiadis "), pursuant to the provisions of Section 7, paragraph 1 sub a of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft) (the " Decree ") in connection with the intended public offer by Sanofi for all the issued and outstanding ordinary shares in the capital of Kiadis (the " Offer "). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe...

Amsterdam, The Netherlands, November 24, 2020 – Kiadis Pharma N.V . ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative NK-cell-based medicines for the treatment of life-threatening diseases, today announces that Kiadis will participate in the 2020 Piper Sandler 32 nd Annual Virtual Healthcare Conference. Arthur Lahr, the company’s chief executive officer, will participate in a fireside chat and host one-on-one...

This is a press release by Kiadis Pharma N.V. ( Kiadis ), pursuant to the provisions of Sections 5 paragraphs 4 and 5 and 6 paragraph 2 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) (the Decree ) in connection with the intended public offer by Sanofi for all the issued and outstanding ordinary shares in the capital of Kiadis (the Offer ). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any...

Amsterdam, The Netherlands, November 13, 2020 – Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS) , a clinical-stage biopharmaceutical company developing innovative NK-cell-based medicines for the treatment of life-threatening diseases, today announces that five abstracts related to its K-NK-cell therapy platform were accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition being held virtually from December...